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Platinum-based combination chemotherapy has proven to be a
highly effective modality in the treatment of both male and female
germ cell tumours. Clinical use of cisplatin has increased the cure
rate for patients with metastatic disease from 5% to 85% (Einhorn,
1990; Segelov et al, 1994). Unfortunately, cisplatin has both
nephrotoxic and neurotoxic side-effects that limit its clinical
utility. The nephrotoxicity requires that the patient have intravas-
cular volume loading, active diuresis and renal function monitored
during the course of therapy. The morbidity of this treatment
would be significantly reduced if the nephrotoxicity of cisplatin
could be inhibited without effecting the therapeutic efficacy.
The nephrotoxicity of cisplatin may involve a pathway that is
distinct from anti-tumour activity of the drug. The therapeutic
activity of cisplatin has been attributed to its ability to bind DNA,
thereby killing dividing cells (Chu, 1994). The renal proximal
tubule cells, which are the target of cisplatin toxicity, are a non-
dividing cell population. The mechanism of cisplatin nephrotoxi-
city has not yet been elucidated. However, we have discovered that
the nephrotoxicity of cisplatin can be blocked by inhibiting the
enzyme g-glutamyl transpeptidase (GGT), an enzyme present on
the luminal surface of the renal proximal tubule cells (Hanigan et
al, 1994b, 1996). GGT can be blocked in vivo with acivicin, a non-
competitive inhibitor, or a high dose of glutathione can be used as
a competitive inhibitor. Either treatment protects against cisplatin
nephrotoxicity (Hanigan et al, 1994b). GGT is expressed on the
surface of some ovarian tumours (Hanigan et al, 1994a). To deter-
mine whether GGT activity is an essential component of the thera-
peutic effect of cisplatin, we examined a series of human germ cell
tumours for expression for GGT and analysed the relationship
between GGT expression and response to platinum-based therapy.
Germ cell tumours have historically been classified as seminoma-
tous (testicular seminoma and ovarian dysgerminoma) and non-
seminomatous (ovarian yolk sac tumour, embryonal carcinoma of
the testis, choriocarcinoma and teratoma). In this study patients
with seminomatous tumours were grouped together due to some
histological and clinical similarities. Likewise the non-seminoma-
tous testicular tumours (embryonal and mixed tumours) were
grouped with ovarian yolk sac tumours and mixed tumours.
Expression of GGT was determined immunohistochemically in
formalin-fixed, paraffin-embedded tissues with the antibody
GGT129. The GGT129 antibody was developed in our laboratory
and is directed against a 20-amino acid peptide at the C-terminus
of the heavy subunit of human GGT (Hanigan et al, 1996). We
have shown that the level of immunohistochemical staining corre-
lates with the level of GGT activity as measured biochemically
(Hanigan et al, 1996). In this study, percentage of tumour cells
staining positive was analysed in relation to tumour histology, the
stage and grade of the tumour, and response to therapy.
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expression and clinical response to platinum-based chemotherapy was examined in 41 human germ cell tumours. Sections of formalin-fixed,
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or embryonal carcinomas received cisplatin-based chemotherapy following surgery. Twelve had a complete response, while three failed to
respond to platinum-based therapy. There was no correlation between the level of GGT-expression and response to therapy in this group.
Three of the four patients with tumours of mixed histology were treated with cisplatin-based therapy, and had a complete response. Therefore,
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systemic inhibition of GGT would inhibit the nephrotoxic side-effect of cisplatin without interfering with its activity towards germ cell tumours.
Keywords: glutathione; human tumours; platinum-based therapy; chemotherapy
75
British Journal of Cancer (1999) 81(1), 75–79
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0653
Received 3 September 1998
Revised 12 January 1999
Accepted 20 February 1999
Correspondence to: MH Hanigan, Department of Cell Biology, School of
Medicine Box 439, University of Virginia Health Sciences Center,
Charlottesville, VA 22908, USAMATERIALS AND METHODS
Human tissue
The Norwegian Radium Hospital (Oslo, Norway) provided
sections of tumour tissue and clinical information for ten patients
with yolk sac tumours. All other tissue specimens were obtained
from archival files in the Department of Pathology at The
University of Virginia Health Sciences Center (Charlottesville,
VA, USA). Clinical information for patients treated at The
University of Virginia Cancer Center were obtained from The
McIntire Tumour Registry at the University of Virginia. Yolk sac
tumours (also referred to as endodermal sinus tumours) and
dysgerminomas were staged according to The International
Federation of Gynecology and Obstetrics (FIGO) Stage Groupings
for Primary Carcinomas of the Ovary (FIGO, 1988, 1989).
Embryonal tumours and seminomas were staged according to the
TNM staging system (American Joint Committee on Cancer,
1997). All tissues analysed were from the initial surgery and all
were primary tumours, except one sample which was a lymph
node metastasis from a male with a germ cell tumour of mixed
histology. None of the patients had received any therapy prior to
surgery.
Immunohistochemistry
GGT129 is an affinity-purified polyclonal antibody directed
against a 20-amino acid peptide corresponding to the C-terminus
of the heavy subunit of GGT. The antibody was produced and
purified in our laboratory (Hanigan et al, 1996). The procedure for
immunohistochemical staining has been described previously
(Hanigan et al, 1996). Briefly, 5-mm sections of formalin-fixed,
paraffin-embedded tissue were deparaffinized and rehydrated.
Endogenous peroxidase activity was inhibited with 0.3%
hydrogen peroxide in methanol. Endogenous biotin was blocked
with avidin and biotin blocking solutions (Avidin/Biotin Block
Kit, Vector Laboratories Inc., Burlingame, CA, USA). Back-
ground staining was inhibited by incubating the sections for
10min in phosphate-buffered saline containing 1.5% goat serum
(Gibco, Grand Island, NY, USA). Affinity purified GGT129
antibody in 1% bovine serum albumin (BSA) was diluted 1:1000
relative to the starting serum concentration. The sections were
incubated with the primary antibody for 45min. Control slides
were incubated in an equivalently diluted solution of 1% BSA.
The primary antibody was localized with biotinylated anti-rabbit
IgG and avidin-linked peroxidase (Vectastain Elite ABC
Peroxidase Kit) and BioGenex Liquid DAB Substrate Kit
(BioGenex, San Ramon, CA, USA). Slides were incubated for
3min in 0.5% cupric sulphate to enhance the stain and counter-
stained in Gill￿s 3 Hematoxylin (Sigma, St Louis, MO, USA). All
incubations were done at room temperature. A section of normal
human kidney was included as a positive control with each set of
sections stained.
The monoclonal mouse-antihuman antibody, CD68-KP1
(Dakopatts, Glostrup, Demark), was used to immunolocalize histi-
ocytes in a subset of the dysgerminoma and seminoma tissues. The
tissue sections were stained in the Ventana ES automated
immunostainer (Ventana Medical Systems Inc., Tucson, AZ,
USA). The CD68-KP1 antibody was diluted 1:100 and the tissues
were incubated for 32min at 42°C in the primary antibody.
Histopathological assessment
The sections were analysed and scored for immunostaining by two
observers (HFF and MHH). The percentage of tumour cells that
were immunopositive was estimated for each sample.
Response to treatment
Response to treatment was defined as complete response (CR) —
no evidence of disease as determined by two observations not
fewer than 4 weeks apart; stable disease (SD) — measurable lesions
remain of stable size or do not increase more than 25% or decrease
more than 50%; progressive disease (PD) — an increase of 25% or
more in the size of one or more measurable lesions or the appear-
ance of new lesions (Miller et al, 1981).
Statistical analysis
The correlation between GGT expression and the histological clas-
sification of the tumours was analysed for significance with the c2
test with Yates￿ correction for 2 ´2 contingency tables (Glantz,
1992). The correlation between the percentage of tumour cells that
were GGT-positive and tumour stage (stage I vs stages II—IV) was
analysed with a t-test. The correlation between GGT expression
and the response of the tumours to chemotherapy was analysed for
significance with both the Mann—Whitney rank sum test including
a Yates correction for continuity and a correction for ties and by
grouping tumours with low versus high levels of GGT expression
and analysing the data with the Fisher exact test (Glantz, 1992).
RESULTS
Dysgerminomas and seminomas
Seventeen testicular seminomas and four ovarian dysgerminomas
were evaluated for GGT expression and response to therapy. All of
the tumour cells in these 21 malignancies were negative for GGT
staining. GGT-positive non-neoplastic cells were observed in the
stroma of many of these tumours. Immunohistochemical staining
with CD 68 antibody revealed that the GGT-positive cells were
histiocytes.
The patients with seminomas ranged in age from 25 to 57 years.
All were treated surgically. Four patients with localized disease
received no treatment following surgery. One of these four patients
had a distant recurrence at 14 months and was treated with
cisplatin—etoposide and bleomycin. He had a complete response
with no evidence of disease at 5 years. Eleven patients were
treated with radiation following surgery. Nine had no recurrence of
disease. Two had distant metastasis identified 14—22 months after
diagnosis and were then treated with cisplatin—etoposide—
bleomycin. Both had a complete response. One patient had
metastatic disease at the time of surgery. He was treated with
cisplatin—etoposide—bleomycin. He had a complete response with
no evidence of disease at 9 years. One patient received treatment
elsewhere and was lost to follow-up.
Therefore, four patients with metastatic seminomas were treated
with cisplatin-based chemotherapy. All four had a complete
response despite the absent of GGT expression in these tumours.
This high complete response rate to cisplatin-based chemotherapy
among metastatic seminomas is similar to the response rates seen
at other institutions (Einhorn, 1990; Segelov et al, 1994).
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74 years. Two were diagnosed at stage Ia and two were stage IIIc.
All four patients were treated with radiation following surgery.
Three had no subsequent evidence of disease. One of the patients
diagnosed at stage Ia was found to have distant metastasis 6
months after surgery. She was diagnosed in 1978 prior to the wide-
spread availability of cisplatin. She died 1 year after diagnosis.
Ovarian yolk sac tumours and embryonal carcinoma of
the testis
Twelve ovarian yolk sac tumours and four embryonal carcinomas
of the testis were evaluated for expression of GGT (Table 1).
Patients ranged in age from 11 to 69 years of age. Immuno-
histochemical staining for GGT showed that all of the tumours
contained a mixture of GGT-positive and GGT-negative tumour
cells. This finding is in contrast to normal female germ cells and
sperm that are GGT-negative (Hanigan et al, 1996). The stage I
ovarian yolk sac tumours contained a significantly lower
percentage of GGT-positive cells than the stage II, III and IV
tumours (P < 0.01, Figure 1). The testicular embryonal carcinomas
occurred in patients from 20 to 27 years of age. Among the embry-
onal carcinomas, tumours diagnosed at stage II contained only
5—25% GGT-positive cells, while the two neoplasms diagnosed 
at stage III contained 90—100% GGT-positive cells (Table 1, 
Figure 2).
All patients, except one, diagnosed with yolk sac tumour or
embryonal carcinoma were treated with cisplatin-based combina-
tion chemotherapy. The exception was patient no. 3 (Table 1) who
was treated with combination chemotherapy that did not include
cisplatin. Of the 15 patients treated with cisplatin, 12 have had a
complete response to treatment with no subsequent evidence of
disease for 20 months or longer. One patient died 6 months
following the diagnosis and two died at 13 months. There is no
statistically significant correlation between GGT expression and
response to cisplatin-based chemotherapy.
Tumours with mixed histology
Germ cell tumours with mixed histology were also examined for
GGT (Table 2). One tumour, from a 16-year-old female (patient
no. 17), contained both yolk sac tumour and dysgerminoma.
Within the yolk sac portion of the tumour, 5% of the tumour cells
were GGT-positive. All of the dysgerminoma cells were GGT-
negative. Two males, ages 21 and 29, had mixed embryonal carci-
noma and seminoma. The embryonal portions of the tumours were
90% and 50% GGT-positive while the seminomatous portions
were negative. A third male, age 22 years, had a mixed germ cell
tumour with embryonal, choriocarcinomatous and teratomatous
elements. The tumour tissue that was analysed was from a lymph
node metastasis consisted entirely of embryonal carcinoma. Ten
per cent of the tumour cells in the lymph node were GGT-
positive.
Patient no. 18 (Table 2) was diagnosed with stage I disease and
did not receive further treatment. The three patients with advanced
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Table 1 Yolk sac tumours and embryonal carcinomas: GGT immunohistochemical staining and response to treatment
Patient GGT- Survival
number Age Stage positive TMT Response (months) Status
Yolk sac tumour of the ovary
1 21 Ia 5% PVB CR 82 NED
2 12 Ia 25% PE CR 24 NED
3 17 Ic 25% CAOS CR 140 NED
4 19 Ic 70% PE CR 72 NED
5 11 Ic 40% PE CR 48 NED
6 15 Ic 10% PE CR 20 NED
7 24 IIc 75% PEB+RAD CR 96 NED
8 69 IIc 50% PE SD 13 DOD
9 40 IIIc 75% PEB CR 35 NED
10 21 IIIc 75% PE SD 13 DOD
11 32 IV 50% PEB CR 83 NED
12 22 IV 90% PVAC PD 6 DOD
Embryonal carcinoma of the testis
13 20 II 5% PEB/PNB CR 83 NED
14 24 II 25% PNB CR 149 NED
15 27 III 90% PEB CR 97 NED
16 20 III 100% PEB CR 21 NED
TMT, treatment; P, cisplatin; E, etoposide (VP16); B, bleomycin; V, vincristine; A, actinomycin D; C, cyclophosphamide; O, oncovin; S, adriamycin; RAD,
radiation therapy; N, vinblastine; CR, complete response; SD, stable disease; PD, progressive disease; NED, no evidence of disease; DOD, dead of disease.
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Figure 1 Expression of GGT versus tumour stage in ovarian yolk sac
tumours. The percentage of tumour cells that were GGT-positive is shown for
stage I–IV yolk sac tumours. Expression of GGT was significantly lower in
stage I tumours in comparison to higher stage tumours (P < 0.01)disease were all treated with cisplatin—etoposide and bleomycin.
All had a complete response with no evidence of disease more
than 5 years after diagnosis.
GGT expression and response to cisplatin-based
chemotherapy
As shown in Table 3 there is an exact correlation between the
histology of the tumour and the presence of GGT-positive tumour
cells (P < 0.001). All of the tumour cells in the seminomas or
dysgerminomas were GGT-negative, while each of the yolk sac
tumours and embryonal carcinomas contained GGT-positive cells.
Among the tumours of mixed histology the seminomas and
dysgerminomatous components were GGT-negative, while the
yolk sac and embryonal components contained GGT-positive
tumour cells.
None of the patients in this study had treatment prior to surgery.
Of the 22 patients in this study who received cisplatin-based
therapy following surgery, 19 (86%) had no further evidence of
disease. The three patients who had stable or progressive disease
had been diagnosed with yolk sac tumours of the ovary. There is
no correlation in that group between the percentage of tumour
cells that were GGT-positive and response to therapy. Patients
with seminomas, which are completely GGT-negative, and
patients with embryonal carcinomas, which are GGT-positive, all
responded to cisplatin-based combination chemotherapy. Based on
these data we conclude that expression of GGT in the tumour cells
is not necessary for the tumour to respond to cisplatin-based
chemotherapy.
DISCUSSION
In this study human germ cell tumours were analysed for GGT
expression and response to therapy to determine whether expres-
sion of GGT is necessary for response to cisplatin-based
chemotherapy. Immunohistochemical staining showed that all of
the seminomas and dysgerminomas were GGT-negative. The yolk
sac and embryonal germ cell tumours contained GGT-positive
tumour cells. In germ cell tumours of mixed histology the semino-
matous and dysgerminomatous components were GGT-negative
while the yolk sac and embryonal components contained GGT-
positive tumour cells. Twenty-two of the patients in this study were
treated with cisplatin-based chemotherapy. Nineteen have had no
further evidence of disease for 20 months or more. Three patients
with yolk sac tumours failed to achieve a complete response.
Patients with seminomas, which are GGT-negative, and patients
with mixed tumors containing seminomatous and dysgerminoma-
tous components all had a complete response to cisplatin-based
chemotherapy. Therefore, expression of GGT is not necessary for
germ cell tumours to respond to cisplatin-based chemotherapy.
Our previous studies have shown that sperm and normal female
oocytes are GGT-negative (Hanigan et al, 1996). Sepulveda and
co-workers reported that GGT is expressed in midgestational yolk
sacs of mouse embryos and in mouse yolk sac carcinoma cells
(Sepulveda et al, 1995). All of the yolk sac and embryonal
tumours in this study contained GGT-positive cells. Van￿T Sant
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Figure 2 Immunohistochemical detection of GGT in an embryonal
carcinoma. The embryonal carcinoma from patient no. 16. Note that in many
of the tumour cells the stain is localized to the surface membrane which is
the location of GGT in normal tissues in which it is expressed
Table 2 Germ cell tumours with mixed histology: GGT immunohistochemical staining and response to treatment
Patient GGT- Survival
number Age Stage Histology positive TMT Response (months) Status
Female
17 16 IIIc Yolk sac 5% PEB CR 76 NED
Dysgerminoma 0%
Male
18 21 I Embryonal 90% None CR 97 NED
Seminoma 0%
19 29 II Embryonal 50% PEB CR 67 NED
Seminoma 0%
20a 22 II Embryonal 10% PEB CR 80 NED
TMT, treatment; P, cisplatin; E, etoposide (VP16); B, bleomycin; CR, complete response; NED, no evidence of disease. aThe pathology report for this patient
stated that tumour was a mixture of embryonal carcinoma, teratoma and choriocarcinoma. The tissue examined for this study was a lymph node metastasis that
included only embryonal carcinoma.and co-workers reported that GGT activity was elevated in serum
from patients with non-seminomatous germ cell tumours (Van￿T
Sant et al, 1984). None of the patients in the study had liver metas-
tasis prompting the investigators to suggest that the enzyme found
in the serum was synthesized by the tumour. They found that stage
III patients who had an elevated serum level of GGT at the time of
diagnosis had significantly higher mortality than those without
initially elevated GGT.
Tumours that are GGT-positive are able to use extracellular
glutathione as a secondary source of cysteine (Hochwald et al,
1996). GGT cleaves the g-glutamyl bond of extracellular
glutathione, initiating its hydrolysis into its three constituent
amino acids: glutamic acid, cysteine and glycine (Hanigan et al,
1993). The additional cysteine can be used to increase intracellular
glutathione concentrations (Hanigan, 1995). There are conflicting
data from in vitro studies regarding the relationship between GGT
expression and cisplatin sensitivity (Godwin et al, 1992; Bailey et
al, 1994; Tew et al, 1996). In vitro the effect of GGT is often
masked by the extremely high concentration of cysteine in many
tissue culture media. A recent clinical study of GGT expression in
ovarian surface epithelial carcinomas showed that GGT expression
in the tumour did not alter the response to primary cisplatin-based
chemotherapy (Hanigan et al, 1998).
Inhibition of GGT blocks the nephrotoxicity of cisplatin
(Hanigan et al, 1994b). The kidney contains several unique meta-
bolic pathways which may be responsible for the nephrotoxicity of
cisplatin. One such pathway is the mercapturic acid pathway
(Dekant et al, 1995). Cleavage of glutathione-conjugated
compounds by GGT is the first step in this pathway. Ongoing
research in our laboratory is aimed at identifying the mechanism
by which cisplatin is activated to a nephrotoxin.
In summary, GGT activity is essential for the nephrotoxicity of
cisplatin but does not affect the response of germ cell tumours to
cisplatin-based chemotherapy. If the nephrotoxicity of cisplatin is
via a metabolic pathway that is specific to the kidney then it may
be possible to block the nephrotoxicity of cisplatin without
inhibiting its anti-tumour activity. Understanding the mechanism
of cisplatin toxicity towards both germ cell tumours and non-
dividing tissues such as the kidney will provide important informa-
tion with which to further increase the therapeutic efficacy of this
widely used anti-tumour agent.
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Table 3 Human germ cell tumours: expression of GGT and response to cisplatin-based chemotherapy
GGT-positive tumours/ Number of tumours Complete response
total number of treated with cisplatin- following cisplatin-
Histology tumours analysed based chemotherapy based chemotherapy
Seminoma 0/17 4 100%
Dysgerminomas 0/4 0 –
Yolk sac 12/12 11 73%
Embryonal 4/4 4 100%
Mixed histology 4/4 3 100%